Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
Rhea-AI Summary
Envoy Medical (NASDAQ: COCH) announced issuance of three patents — one U.S. and two Hong Kong — strengthening its fully implanted cochlear implant IP portfolio.
The U.S. Patent No. 12,544,564 (Feb 10, 2026) covers improved input signal-to-noise ratio. Hong Kong patents HK40102155 and HK40107235 cover hearing-aid combination functionality and electrode impedance diagnostics. The company noted IP importance as it advances toward potential PMA submission; the Acclaim device holds FDA Breakthrough Device designation and is in a U.S. pivotal trial.
Positive
- U.S. Patent No. 12,544,564 granted Feb 10, 2026 for improved input signal-to-noise ratio
- Two Hong Kong patents (HK40102155, HK40107235) expand system flexibility and diagnostics
- FDA Breakthrough designation for Acclaim and ongoing U.S. pivotal trial
Negative
- No PMA approved yet — regulatory approval and commercialization remain pending
- Acclaim still investigational in a pivotal U.S. trial; commercialization timing is uncertain
Key Figures
Market Reality Check
Peers on Argus
COCH was down 3.37% with light volume while sector peers showed mixed moves: RBOT up 8.41%, VVOS up 4.29%, IINN down 3.24%, TRIB down 3.06%. With 2 peers also moving down and a scanner summary citing broader dynamics (median move about -3.2% for decliners), part of COCH’s weakness pre-patent news aligned with sector forces rather than being purely idiosyncratic.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Clinical & financing update | Positive | -6.3% | Upsized financing and pivotal trial progress with near-term enrollment completion. |
| Feb 17 | Clinical trial update | Positive | +14.8% | Nearing full enrollment and reiterating timeline to potential PMA submission. |
| Feb 12 | Offering closing | Negative | -20.5% | Closing of upsized public offering with significant new shares and warrants. |
| Feb 11 | Offering pricing | Negative | +69.2% | Pricing of large equity offering at $0.40 per share with attached warrants. |
| Dec 18 | Enrollment milestone | Positive | -0.4% | Pivotal Acclaim trial reached midway enrollment with timelines reaffirmed. |
Recent history shows mixed reactions: positive clinical and financing news often met with selloffs, while one financing pricing event produced a strong rally. Overall, there are more divergence events than alignments between news tone and next-day price moves.
Over the last few months, Envoy Medical has focused on funding and advancing its fully implanted Acclaim cochlear implant. In February 2026, it priced and then closed an upsized public offering linked to up to $78.0M, extending cash runway but prompting a sharp -20.52% reaction after closing. Clinical updates in December 2025 and mid‑February 2026 highlighted steady enrollment toward pivotal trial completion and a potential PMA submission in Q2 2027, yet some of these positive updates were followed by negative price moves. Against this backdrop, the new patent issuances add to a steadily building strategic IP and clinical story.
Market Pulse Summary
This announcement expands Envoy Medical’s intellectual property with three patents covering signal processing, integration with external hearing aids, and electrode impedance diagnostics for its fully implanted cochlear implant systems. These patents complement the Acclaim device’s existing FDA Breakthrough Device Designation from 2019 and its ongoing pivotal trial. Recent history shows frequent financings and mixed share-price reactions to otherwise positive updates, so investors may focus on how this strengthened patent estate supports future PMA submission, commercialization plans, and differentiation within hearing implants.
Key Terms
cochlear implant medical
signal-to-noise ratio technical
impedance diagnostics medical
compliance voltage technical
Premarket Approval (PMA) regulatory
Breakthrough Device Designation regulatory
pivotal clinical trial medical
AI-generated analysis. Not financial advice.
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry.
"We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs," said Brent Lucas, Chief Executive Officer of Envoy Medical. "As the industry realizes the wisdom and flexibility of our approach, we will have a strong patent portfolio to help protect our leadership position as a first mover with substantial differentiation."
Management believes that as the Company progresses toward potential Premarket Approval (PMA) submission and commercialization, the strength and breadth of its intellectual property portfolio will be an increasingly important asset, both strategically and competitively.
The United States Patent and Trademark Office granted U.S. Patent No. 12,544,564 on February 10, 2026, titled "Cochlear Implant System with Improved Input Signal-to-Noise Ratio." This patent relates to cochlear implant systems having a signal processor configured to filter a received input signal to attenuate a first pulse rate in the input signal and to output a stimulation signal based on the filtered input signal to cause a stimulator to provide electrical stimulation at the first pulse rate.
In addition, the Hong Kong Patent Office granted two complementary patents. Hong Kong Patent No. HK40102155, titled "Combination Hearing Aid and Cochlear Implant System." This patent relates to cochlear implant systems and receiving a status indicator signal indicative of whether an external auditory aid device (e.g., a hearing aid) is active and updating a transfer function of a signal processor of the cochlear implant system to compensate for operation of the external auditory aid device if it is active. This capability relates to the potential flexibility allowed by our system by leveraging the natural ear to pick up sound, which allows for (but does not require) the use of other devices in the ear.
Hong Kong Patent No. HK40107235, titled "Cochlear Implant System with Electrode Impedance Diagnostics," relates to impedance diagnostics within a cochlear implant system. This patent relates to impedance diagnostics in cochlear implant systems. A cochlear implant system can determine an impedance associated with a current path from a source element to a return electrode and determine one or more stimulation parameters for the source element based on the impedance. An example stimulation parameter can include a compliance voltage for the source element to provide a prescribed current.
The Acclaim® cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial. For more information on the trial, visit www.envoymedical.com/acclaim-pivotal.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain additional patents and develop future products or product improvements; the ability to obtain and maintain compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and the amount of capital required to complete the FDA pivotal trial and early commercialization; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submission to the FDA; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284835
FAQ
What patents did Envoy Medical (COCH) receive on February 23, 2026?
How do Envoy Medical's new patents affect COCH shareholders?
Does Envoy's U.S. patent No. 12,544,564 improve hearing performance?
What do the Hong Kong patents HK40102155 and HK40107235 cover for COCH?
What is the regulatory status of Envoy's Acclaim device (COCH)?
